Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Phibro Animal Health (NASDAQ:PAHC) is the #1 top healthcare stock out of 1122 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 47, which is 22 points higher than the healthcare sector average of 25. It passed 17 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 63.36% over the past year, overperforming other healthcare stocks by 114 percentage points.

Phibro Animal Health has an average 1 year price target of $24.00, a downside of -14.29% from Phibro Animal Health's current stock price of $28.00.

Phibro Animal Health stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Phibro Animal Health, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

Enhabit (NYSE:EHAB) is the #2 top healthcare stock out of 1122 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Enhabit (NYSE:EHAB) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Enhabit (NYSE:EHAB) has a Due Diligence Score of 7, which is -18 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates EHAB as a "A".It passed 2 out of 33 due diligence checks and has weak fundamentals. Enhabit has seen its stock lose -12.67% over the past year, overperforming other healthcare stocks by 38 percentage points.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top healthcare stock out of 1122 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 65, which is 40 points higher than the healthcare sector average of 25. It passed 21 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 38.76% over the past year, overperforming other healthcare stocks by 90 percentage points.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 12.56%, which is 11 percentage points higher than the healthcare sector average of 1.94%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 32.4% indicates that its high dividend yield is sustainable for the long-term.

Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of 7.92%, which is 6 percentage points higher than the healthcare sector average of 1.94%.

Cryo Cell International's dividend payout ratio of 5,000% indicates that its high dividend yield might not be sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 7.01%, which is 5 percentage points higher than the healthcare sector average of 1.94%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 160.3% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.44% in the last day, and up 0.61% over the last week. Theratechnologies was the among the top gainers in the healthcare sector, gaining 35.59% yesterday.

Theratechnologies shares are trading higher after the company announced it entered into a binding arrangement agreement to be acquired by CB Biotechnology.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Centene (NYSE:CNC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Centene has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Centene's stock has dropped -50.1% in the past year. It has overperformed other stocks in the healthcare sector by 1 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 18.54% in the past year. It has overperformed other stocks in the healthcare sector by 69 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 4.11% in the past year. It has overperformed other stocks in the healthcare sector by 55 percentage points.

51.08% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 46.86% over the next year.

5.16% of healthcare stocks have a Zen Rating of A (Strong Buy), 10.91% of healthcare stocks are rated B (Buy), 45.68% are rated C (Hold), 25.42% are rated D (Sell), and 12.83% are rated F (Strong Sell).